111 articles
All articles →Foundayo's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.
A GLP-1 dose tracker logs which milligram you took on which date and follows your titration — Wegovy 0.25→2.4, Zepbound 2.5→15. See how to track and share it.
A GLP-1 shot tracker logs each weekly injection — date, rotated site, and missed-dose window for Wegovy, Ozempic & tirzepatide. See exactly how to track a shot.
Choosing an injection tracker app for GLP-1? Here are the must-have features — site-rotation body map, weekly reminders, dose log, missed-dose logic — and why it beats paper.
Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.
Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.
In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.
A GLP-1 side effect tracker logs each symptom with its severity, timing vs your dose, and food link — so you spot patterns and know when the log says see a doctor.
A Foundayo tracker logs your daily dose, weight trend, protein & side effects. Learn exactly what to track on the once-daily oral GLP-1 pill orforglipron and why.
An oral Wegovy tracker logs your daily dose, the empty-stomach fasting window, weight trend, protein & side effects. Here's what to track on the Wegovy pill.
An orforglipron tracker logs your daily dose, titration step, weight trend, protein & side effects. Learn what to track on Foundayo, the oral GLP-1 pill, and why.
Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.
The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.
Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.
Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A Mounjaro tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on tirzepatide and why it matters.
Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.
An Ozempic tracker logs your dose day, injection site, weight trend, blood sugar & side effects. Learn what to track on semaglutide and why it matters.
A retatrutide tracker guide: what the investigational triple agonist is, trial results so far (~24% weight loss in Phase 2), its status, and what you'd track.
Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A semaglutide tracker logs your dose, injection site or pill timing, weight trend, protein & side effects across Ozempic, Wegovy & Rybelsus. Here's what to track.
Looking for a Shotsy alternative on Ozempic or Zepbound? What Shotsy's shot tracker does well, where it stops, and how an all-in-one GLP-1 app compares.
The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.
A tirzepatide tracker logs your weekly dose, injection site, weight trend, protein & side effects — for Mounjaro or Zepbound. Learn what to track and why.
Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
A Wegovy tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on semaglutide and why it matters.
Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.
A Zepbound tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on tirzepatide and why it matters.
GLP-1 receptor agonists (Wegovy, Mounjaro, Zepbound) produce 15–22% average weight loss (STEP 1, SURMOUNT-1). But STEP 4 reported +11.6%p regain one year after discontinuation — about 78% of weight loss returned. WHO (2022) and ADA Standards (2024) explicitly recommend behavioral therapy alongside pharmacotherapy, and STEP 3 (JAMA 2021) showed Intensive Behavioral Therapy in combination achieved nearly 3× the weight loss of standard-care combination (−16% vs −5.7%). HAVIT structures this in 3 stages — pre-medication (M0), adaptation (M1), maintenance/discontinuation (M2) — integrating drugs, muscle preservation, and behavior learning. HAVIT does not prescribe GLP-1; prescription, dosing, and discontinuation remain the physician's domain.
FDA testing found 30% of compounded semaglutide samples had purity issues, while brand Wegovy maintains 99.5%+ consistency—but the full safety picture is more nuanced than headlines suggest.
Creatine supplementation during Wegovy use can help preserve 1-2 lbs more lean mass over 12 weeks when combined with resistance training—a meaningful edge during rapid weight loss.
Semaglutide fundamentally alters how your brain processes alcohol reward, cutting tolerance by 40-60% and creating new hypoglycemia risks that require careful management.
Light to moderate alcohol (1-2 drinks occasionally) appears safe for most on semaglutide, but GLP-1s slow gastric emptying and may intensify effects—know your limits and watch for hypoglycemia.
GLP-1 medications can delay antibiotic absorption by 1-3 hours, but total effectiveness usually remains intact with proper timing adjustments.
GLP-1 receptors in brain regions controlling emotion explain why some people experience anxiety or mood shifts on these medications—most cases improve within 8-12 weeks.
Semaglutide delays gastric emptying enough to reduce oral contraceptive absorption by up to 24%—backup methods during the first 4-8 weeks are worth considering.
Weight loss from GLP-1 drugs often requires reducing blood pressure medication doses to prevent dizziness and falls from hypotension.
Moderate coffee consumption (2-3 cups) appears to complement GLP-1 medications through adenosine receptor crosstalk, but timing and amount matter significantly.
GLP-1 drugs delay stomach emptying by 30-50%, causing caffeine to absorb slower but last longer—here's how to recalibrate your coffee routine.
Compounded semaglutide carries real risks—sterility failures, inconsistent dosing, and unverified ingredients—that FDA-approved versions don't have.
GLP-1 drugs slow your stomach by 40%, making soluble fiber your ally and insoluble fiber a potential problem—here's the science-backed swap.
GLP-1 medications slow gut transit by 30-40%, requiring soluble fiber over insoluble and strategic hydration timing rather than generic constipation advice.
GLP-1 drugs reduce saliva flow significantly—here's how to protect your teeth with evidence-based daily habits and professional interventions.
GLP-1 drugs alone rarely cause low blood sugar, but combining them with insulin or sulfonylureas changes everything—here's how to adjust doses safely.
Increase your GLP-1 dose when weight loss stalls for 4+ weeks AND you're tolerating your current dose well—but never rush the timeline.
GLP-1 drugs reduce food and fluid intake, creating electrolyte deficits that cause fatigue, cramps, and heart palpitations—here's how to prevent them.
Wait 2-4 hours after injection before intense exercise—blood flow changes during workouts can alter GLP-1 absorption rates by up to 30%.
Losing weight at 0.5-1% body weight weekly, prioritizing protein at 1.2g/kg, and maintaining facial muscle tone can significantly reduce the gaunt 'Ozempic face' appearance.
GLP-1 medications rewire your brain's reward pathways, creating genuine taste aversions—not just reduced appetite—that you can strategically manage.
Rapid weight loss on GLP-1s disrupts bile chemistry, but strategic fat intake, gradual loss rates, and prophylactic ursodiol can cut gallstone risk by up to 80%.
Rapid weight loss on GLP-1s can cause bile stasis and gallstones—strategic fat intake and gradual dosing help prevent complications.
Most GLP-1 stomach slowing resolves within 8-12 weeks, but persistent vomiting, severe bloating, or unintended weight loss beyond 5% signals true gastroparesis requiring evaluation.
Most GLP-1 stomach slowdown resolves in weeks, but specific warning signs—like vomiting solid food 6+ hours after eating—signal true gastroparesis requiring immediate medication pause.
Hair loss on GLP-1 medications stems from rapid weight loss triggering telogen effluvium, not the drug itself—adequate protein intake (1.2-1.5g/kg) can prevent and reverse it.
Hair loss on GLP-1 medications is usually telogen effluvium from rapid weight loss, not the drug itself—most people see regrowth within 6-12 months.
GLP-1 drugs like Ozempic have a built-in safety mechanism that makes true hypoglycemia extremely rare in people without diabetes—under 1% in clinical trials.
GLP-1 medications show anti-inflammatory effects that may benefit metabolic health, but current evidence doesn't suggest increased infection risk in most users.
Abdomen injections show 11-15% faster absorption than thigh sites, but all three locations deliver equivalent total medication over the weekly cycle.
Rotating injection sites using a clock-face pattern with 2cm spacing prevents tissue damage and maintains up to 25% better medication absorption over time.
Warming your pen for 30 minutes, using a proper skin pinch, and choosing the right injection site can reduce GLP-1 injection pain by up to 60%.
Take iron supplements 2-4 hours before your GLP-1 dose on an empty stomach with vitamin C to maximize absorption despite altered gastric conditions.
GLP-1 medications can stress kidneys through dehydration from nausea and vomiting—aim for 2.5-3L water daily and monitor kidney function every 3-6 months.
Most people on semaglutide need baseline kidney tests plus monitoring every 3-6 months, especially if experiencing significant GI side effects causing dehydration.
GLP-1 drugs delay gastric emptying by 2-4 hours, requiring levothyroxine to be taken 60+ minutes before any food and TSH monitoring every 6-8 weeks during dose adjustments.
Five-year cardiovascular outcome trials show semaglutide reduces heart events by 20% with manageable side effects, though muscle loss and rare thyroid concerns warrant ongoing monitoring.
GLP-1 medications like semaglutide reduce cardiovascular events by 20% even when accounting for weight loss, suggesting direct heart-protective effects.
GLP-1 medications stay stable at room temperature for 14-56 days depending on type, but temperatures above 86°F can degrade peptides within hours.
Morning GLP-1 injections (7-9 AM) align with natural cortisol peaks and may improve efficacy by 23% compared to evening doses, according to 2025 chronobiology research.
GLP-1 medications can dramatically increase fertility by restoring ovulation—sometimes within 8 weeks—making contraception review essential for anyone not planning pregnancy.
Current evidence suggests GLP-1 medications may actually improve mood for most users, though individual responses vary significantly based on brain receptor distribution.
GLP-1 and metformin work through completely different pathways, creating a 1+1=3 effect for blood sugar control and weight management.
Your recovery window depends entirely on which GLP-1 you take—weekly formulations give you 48-72 hours of flexibility, while daily ones need action within 12 hours.
If you're within 5 days of your missed Ozempic dose, take it immediately; beyond that, skip to your next scheduled day to avoid overlapping doses.
Distributing 1.2-1.6g protein per kg across 4 meals with 30g+ leucine-rich portions at each sitting preserves significantly more muscle during GLP-1 therapy than total daily protein alone.
GLP-1 medications slow stomach emptying by 40-60%, so eating smaller, low-fat meals and timing food around your body's new rhythm dramatically reduces nausea.
GLP-1 medications slow stomach emptying while NSAIDs irritate the stomach lining—together, they can significantly increase GI complications, but safer alternatives exist.
GLP-1 medications can delay oral contraceptive absorption by 1-4 hours, but current evidence suggests effectiveness remains intact when pills are taken consistently.
The key difference between common GLP-1 nausea and pancreatitis is pain location, radiation pattern, and whether eating makes it worse or better.
Most GLP-1 stomach discomfort is normal, but specific pain patterns, timing, and accompanying symptoms can signal the rare but serious complication of pancreatitis.
GLP-1 medications improve PCOS symptoms through both weight-dependent and weight-independent mechanisms, with 40% of metabolic benefits occurring regardless of pounds lost.
PPIs and GLP-1s can generally be combined safely, but timing and dosing adjustments matter—especially in the first 8 weeks of treatment.
Preventing weight regain after GLP-1 medications requires reversing metabolic adaptation through strategic protein timing, resistance training, and building the habits the medication gave you time to develop.
Triple agonist retatrutide achieved 24% weight loss in trials, outpacing dual agonist tirzepatide (21%) and mono agonist semaglutide (15%), but with distinct side effect profiles worth understanding.
Keep tabs on muscle mass during GLP-1 therapy using simple grip strength tests at home and periodic DEXA scans, with clear benchmarks that tell you when it's time to make changes.
Supporting collagen synthesis during rapid GLP-1 weight loss requires specific nutrients, timing, and lifestyle factors—not just hoping for the best.
GLP-1 medications can improve sleep quality primarily through weight loss reducing sleep apnea, though direct brain effects on orexin pathways may also play a role.
GLP-1 agonists lower cholesterol independently of statins by reducing intestinal absorption and liver production, creating a powerful dual-mechanism approach to cardiovascular protection.
Most patients should stop weekly GLP-1 medications 7 days before surgery, but daily formulations only need 24 hours—timing depends on your specific drug and procedure type.
Same molecule, different dosing—switching between semaglutide brands requires careful timing and dose matching to avoid gaps in coverage or doubled-up side effects.
Track TSH and calcitonin at baseline, 6 months, then annually during GLP-1 therapy—most thyroid changes are benign but catching outliers early matters.
Thyroid monitoring on GLP-1s depends on your personal and family history—most people need minimal surveillance, but certain risk factors change everything.
Unopened Ozempic pens survive up to 6 weeks at room temperature (under 86°F), but smart cooling strategies can extend protection during longer trips.
GLP-1 users need targeted supplementation of B12, iron, vitamin D, and zinc due to reduced food intake and altered absorption—timing matters as much as dosage.
GLP-1 medications reduce stomach acid by up to 40%, impairing B12 absorption—sublingual or injectable forms bypass this issue entirely.
GLP-1 plateaus around month 6 are biologically predictable—metabolic adaptation, not medication failure, is usually the culprit, and strategic interventions can restart progress.
Most people notice food noise reduction between weeks 4-8, with significant quieting by week 12 as doses escalate and brain reward pathways recalibrate.
Aim for 1.2-1.6 grams of protein per kilogram of body weight daily while on GLP-1 medications to minimize muscle loss during weight loss.
Train heavy 3x weekly with protein timing around workouts to preserve muscle while GLP-1 medications accelerate your fat loss.
Current guidelines recommend stopping semaglutide at least 2 months before conception, though some fertility specialists now suggest 3 months for optimal outcomes.
Most semaglutide-related hair loss stems from rapid weight loss triggering telogen effluvium, not the drug itself—and it typically resolves within 6-9 months with proper nutrition.
Slower Mounjaro titration (6-8 weeks per dose vs standard 4 weeks) reduces nausea by 67% with identical weight loss outcomes at 72 weeks.
Mounjaro GI side effects typically resolve 2-3 weeks faster than Wegovy's, with 78% of patients symptom-free by week 8 versus week 12.
Wait one week after your last Ozempic dose, start Mounjaro at 2.5mg regardless of your previous semaglutide dose, and expect 2-3 weeks of GI adjustment.
Getting Wegovy covered requires strategic documentation, persistence through appeals, and understanding your insurer's specific criteria—here's exactly how to do it.
GLP-1 drugs slow gastric emptying and compete for liver enzymes, making alcohol hit faster and harder—most patients report 40-60% reduced tolerance.
Same molecule, different missions: Ozempic maxes at 2mg for blood sugar control while Wegovy goes to 2.4mg for weight loss, and insurance treats them as completely separate medications.
Large-scale 2025 studies show GLP-1 drugs may actually reduce depression risk by 12%, though some individuals experience mood changes requiring monitoring.
Schedule intense workouts 3-4 days after injection when nausea peaks have passed, and use injection day for lighter movement like walking.
GLP-1 medications alter gut serotonin production and slow medication absorption, requiring strategic timing adjustments when taking SSRIs or SNRIs.
Rapid weight loss—not GLP-1 drugs directly—drives most bone density decline, and a targeted calcium-vitamin D protocol can largely prevent it.
Emerging research suggests some people can maintain weight loss on reduced GLP-1 doses, but individual variability makes personalized protocols essential.
Everything you need to lose weight, preserve muscle, and build healthier habits—all in one AI-powered app.
Free to download. In-app purchases may apply.
